Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT03048084 |
| Seizure Treatment in Glioma(STING) |
| recruiting |
| Phase 4 |
| 120 |
| Leiden University Medical CenterOTHER |
| 1 |
| Aug 26, 2026 |
| clinicaltrials |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | recruiting | Phase 4 | 16 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06625047 | Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy | completed | Phase 4 | 30 | Mayo ClinicOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07546669 | Efficacy of Zoster Vaccination in Glioblastoma Patients(STARGATE) | not yet recruiting | Phase 4 | 230 | University Hospital, EssenOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT05342883 | GammaTile and Stupp in Newly Diagnosed GBM(GESTALT) | active not recruiting | Phase 4 | 61 | GT Medical Technologies, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05900908 | Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy(PATHWAyS) | withdrawn | Phase 4 | 0 | GT Medical Technologies, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT05235737 | The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab(PIRG) | unknown | Phase 4 | 36 | Medical University of SilesiaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT04650204 | Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy | terminated | Phase 4 | 4 | Mayo ClinicOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00686725 | Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) | completed | Phase 4 | 99 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT01756729 | Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | terminated | Phase 4 | 13 | NovoCure Ltd.INDUSTRY | 1 | Mar 2, 2016 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials